Table 1

Baseline patient characteristics

CharacteristicPatients (n=26)
Age,* years, median (min–max)67.5 (48–89)
Race/ethnicity
 White22 (85)
 Other4 (15)
ECOG performance status, n (%)
 023 (88)
 13 (12)
Gleason Score, n (%)
 60 (0)
 75 (19)
 ≥820 (77)
 Unknown1 (4)
Median PSA,† ng/mL (IQR)29.6 (12.2–77.3)
Presence of visceral disease, n (%)3 (11)
Prior local therapies, n (%)
 Prostatectomy16 (62)
 Radiation therapy13 (50)
Prior systemic therapies, n (%)
 Docetaxel6 (23)
 Sipuleucel-T13 (50)
 Radium-2234 (15)
 Bicalutamide11 (42)
 Abiraterone (single-agent)14 (54)
 Enzalutamide (single-agent)12 (46)
 Any next-generation hormonal therapy (NHT)19 (73)
NHT sequencing/combinations
 Abiraterone then enzalutamide5 (19)
 Enzalutamide then abiraterone4 (15)
 Abiraterone plus enzalutamide2 (8)
 Abiraterone plus apalutamide2 (8)
Median prior systemic therapies, n (IQR)3 (2–3)
  • *IQR for age is (59, 73).

  • †PSA is provided for patients who received at least two doses of study treatment and had at least one follow-up visit (n=25).

  • ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen.